Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.69 |
| ▸ | F2R | P25116 | 2/20 | 0.64 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.59 |
| ▸ | RAB9A | P51151 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10069980 | 0.83 | KMT2A (0.73) | GAAF2RHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL5142687 | 0.83 | GAA (0.77) | GAAHPGDALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL29893001 | 0.83 | GAA (0.67) | GAAHPGDALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL19984585 | 0.83 | GAA (0.67) | GAAHPGDALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL5690831 | 0.81 | GAA (1.00) | GAAF2RHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL2608537 | 0.81 | MEN1 (0.70) | GAAF2RHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL3652608 | 0.81 | ALDH1A1 (0.60) | GAAF2RHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL11795655 | 0.81 | SMN1; SMN2 (0.63) | GAAF2RHPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL22742984 | 0.80 | GAA (0.63) | GAAHPGDALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL7429227 | 0.80 | GAA (0.73) | GAAHPGDALDH1A1SMN1; SMN2RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160297812-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2016-10-13 | — | — | US | disclosed |
| US-8778966-B2 | Quinolinone derivatives as PARP and tank inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-8664241-B2 | Indazole inhibitors of the Wnt signal pathway and therapeutic uses thereof | SAMUMED, LLC (US) | 2014-03-04 | — | — | US | disclosed |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | VIALARD JORGE EDUARDO (BE) | 2013-01-17 | — | — | US | disclosed |
| US-8299256-B2 | Quinolinone derivatives as PARP and TANK inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2012-10-30 | — | — | US | disclosed |
| EP-2134691-B1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-01-25 | — | — | EP | disclosed |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-01 | — | — | US | disclosed |
| EP-2134691-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008107478-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2008-09-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297812-A1 | INDAZOLE INHIBITORS OF THE WNT SIGNAL PATHWAY AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | GAA 2480/4885F2R 2511/4885HPGD 635/4885 |
| US-20100168065-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | GAA 3465/4885F2R 1003/4885HPGD 1677/4885 |
| US-20130018017-A1 | QUINOLINONE DERIVATIVES AS PARP AND TANK INHIBITORS | PARP1, PARP11, PARP3 | GAA 3465/4885F2R 1003/4885HPGD 1677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.